| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Schmid, C, et al.
(författare)
-
Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
- 2022
-
Ingår i: Bone marrow transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 57:2, s. 215-223
-
Tidskriftsartikel (refereegranskat)abstract
- We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in complete hematologic remission (CHR) after allogeneic stem cell transplantation (alloSCT). DLI were applied preemptively (preDLI) for minimal residual disease (MRD, n = 23) or mixed chimerism (MC, n = 169), or as prophylaxis in high-risk patients with complete chimerism and molecular remission (proDLI, n = 126). Median interval from alloSCT to DLI1 was 176 days, median follow-up was 7.0 years. Five-year cumulative relapse incidence (CRI), non-relapse mortality (NRM), leukemia-free and overall survival (LFS/OS) of the entire cohort were 29.1%, 12.7%, 58.2%, and 64.3%. Cumulative incidences of acute graft-versus-host disease (aGvHD) grade II–IV°/chronic GvHD were 11.9%/31%. Nineteen patients (6%) died from DLI-induced GvHD. Age ≥60 years (p = 0.046), advanced stage at transplantation (p = 0.003), shorter interval from transplantation (p = 0.018), and prior aGvHD ≥II° (p = 0.036) were risk factors for DLI-induced GvHD. GvHD did not influence CRI, but was associated with NRM and lower LFS/OS. Efficacy of preDLI was demonstrated by decreasing MRD/increasing blood counts in 71%, and increasing chimerism in 70%. Five-year OS after preDLI for MRD/MC was 51%/68% among responders, and 37% among non-responders. The study describes response and outcome of DLI in CHR and helps to identify candidates without increased risk of severe GvHD.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Parakhonskiy, Bogdan, V, et al.
(författare)
-
A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers
- 2021
-
Ingår i: APPLIED MATERIALS TODAY. - : Elsevier. - 2352-9407. ; 25
-
Tidskriftsartikel (refereegranskat)abstract
- To mitigate side effects in systemic administration, anticancer drugs are encapuslated in nanocontainers. The nanocontainers are impermeable through normal vessel walls but can permeate and retain in the tumor, albeit their diffusive transport in the tumor interstitium towards pharmacological targets is drastically hindered by the tumor microenvironment resulting in a compromised therapeutic efficacy. We introduce a new drug delivery concept, which relies on drug container passive accumulation in the tumor vasculature followed by an hours-scale release of small-molecule payload that cross the capillary walls to the tumor interstitium and permeates the tumor parenchyma. To demonstrate this approach, a colloidal solution of geology-inspired sub-micron vaterite particles (VPs) loaded with photosensitiser drug porphyrazine was used to deliver and visualise porphyrazine biodistribution in the tumors in vivo . The tumor uptake of polyethylene-glycol-coated gold nanorods and porphyrazine was enhanced c.a 4-fold and 1.8-fold, respectively, when formulated in VP containers. The tumor uptake of similar to 30%ID/g much higher than the field average was achieved and enabled successful photodynamic therapy.
|
|
